# CHANNEL THERAPEUTICS CORPORA (CHRO)

> Institutional ownership reported to the SEC as of Q2 2025, from Form 13F filings. Source: https://holderbook.com/stocks/CHRO/

- Reporting holders: 5
- Reported value: $187.3K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [MILLENNIUM MANAGEMENT LLC](https://holderbook.com/funds/1273087-millennium-management-llc/) | $172.3K | 136,712 | 0.0% | 1 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $14.1K | 10,435 | 0.0% | 2 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $822 | 652 | 0.0% | 2 |
| [Tower Research Capital LLC (TRC)](https://holderbook.com/funds/1533421-tower-research-capital-llc-trc/) | $107 | 85 | 0.0% | 5 |
| [BANK OF AMERICA CORP /DE/](https://holderbook.com/funds/70858-bank-of-america-corp-de/) | $24 | 19 | 0.0% | 5 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q2 2025 | 5 | $187.3K |
| Q1 2025 | 9 | $846.2K |
| Q4 2024 | 4 | $16.0K |
| Q3 2024 | 5 | $59.6K |
| Q2 2024 | 5 | $290.3K |
| Q1 2024 | 1 | $659.9K |